Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alto Neuroscience Inc. | ALTO-100 | Bipolar depression | Phase 2b | Data Released | oral | Psychiatric |
| Alto Neuroscience Inc. | ALTO-100 | Post-traumatic stress disorder (PTSD) | Phase 2/3 | Trial Planned | oral | Psychiatric |
| Alto Neuroscience Inc. | ALTO-300 | Major Depressive Disorder (MDD) | Phase 2b | Ongoing | oral | Psychiatric |
| Alto Neuroscience Inc. | ALTO-207 (CTC-501) - (PAX-D) | Treatment-resistant depression (TRD) | Phase 2b | Ongoing | Oral | Psychiatric |
| Alumis Inc. | ESK-001 - (STRIDE) | Moderate-to-severe plaque psoriasis | Phase 2 | Data Released | oral | Immunology: Anti-TNF |
| Alumis Inc. | Envudeucitinib (ESK-001) - (ONWARD2) | Moderate-to-severe plaque psoriasis | Phase 3 | Data Released | Oral | Immunology: Anti-TNF |
| Alumis Inc. | ESK-001 - (LUMUS) | Systemic Lupus Erythematosus (SLE) | Phase 2b | Enrollment Conclusion | Oral | Immunology |
| Alumis Inc. | ESK-001 - (ONWARD3) | Moderate-to-severe plaque psoriasis | Phase 3 | Enrollment Initiation | oral | Immunology: Anti-TNF |
